Literature DB >> 772922

Prevention of lethal pseudomonas bacteremia with epimerase-deficient E. coli antiserum.

E J Ziegler, J A McCutchan, H Douglas, A I Braude.   

Abstract

All of these experiments demonstrate that despite many microbiologic differences between Pseudomonas and the enteric rods, there is a close immunologic relationship between their endotoxin cores. These studies also show that by genetic manipulation we can unmask a protective antigen for preparing antiserum with a broad range of activity, even in the face of neutropenia. Production of potent human J5 antiserum is a safe, simple procedure, making it possible to consider endotoxin core antibody treatment of all Gram negative bacteremia in patients regardless of the causative organism.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 772922

Source DB:  PubMed          Journal:  Trans Assoc Am Physicians        ISSN: 0066-9458


  21 in total

Review 1.  Bloodstream infections: epidemiology, pathophysiology and therapeutic perspectives.

Authors:  R Salomão; O Rigato; A C Pignatari; M A Freudenberg; C Galanos
Journal:  Infection       Date:  1999 Jan-Feb       Impact factor: 3.553

2.  Passive immunization to outer membrane proteins MLP and PAL does not protect mice from sepsis.

Authors:  Catherine H Valentine; Judith Hellman; Laura K Beasley-Topliffe; Aranya Bagchi; H Shaw Warren
Journal:  Mol Med       Date:  2006 Sep-Oct       Impact factor: 6.354

Review 3.  Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.

Authors:  I G Mitov; D G Terziiski
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

Review 4.  Immunotherapeutic advances in the treatment of gram-negative bacterial sepsis.

Authors:  D L Dunn
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

Review 5.  New insights into the epidemiology, pathogenesis and therapy of Pseudomonas aeruginosa infections.

Authors:  S J Cryz
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

6.  Antiserum against Escherichia coli J5: a re-evaluation of its in vitro and in vivo activity against heterologous gram-negative bacteria.

Authors:  M Trautmann; H Hahn
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

7.  Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide.

Authors:  M I Marks; E J Ziegler; H Douglas; L B Corbeil; A I Braude
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

8.  alpha-GlcNAc-1-->2-alpha-glc, the Salmonella homologue of a conserved lipopolysaccharide motif in the Enterobacteriaceae, elicits broadly cross-reactive antibodies.

Authors:  N A Nnalue
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

Review 9.  Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients.

Authors:  A Cometta; J D Baumgartner; M P Glauser
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

10.  Mechanisms involved in protection provided by immunization against core lipopolysaccharides of Escherichia coli J5 from lethal Haemophilus pleuropneumoniae infections in swine.

Authors:  B W Fenwick; J S Cullor; B I Osburn; H J Olander
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.